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ABSTRACT 
 
Introduction: Multiple myeloma (MM) is a bone marrow plasma cell malignancy characterized by 
wide clinical presentation and heterogeneous genetic background. Despite the recent advances in 
patient outcome, new markers are needed for improving risk prediction and choice of a more 
appropriate therapy. In this perspective, the genetic makeup of MM cells is being better 
characterized by means of next-generation sequencing (NGS) technologies. 
Areas covered: The authors discuss how the application of NGS has improved our knowledge of 
MM biology by discovering its mutational landscape, identifying the operating mutational 
processes, and revealing the clonal composition of tumors and the dynamics of its evolution; and 
how this can have important clinical implications in terms of prognostication, therapeutic choices, 
and response assessment. Finally, the authors provide a quick outlook of future applications of 
these technologies that could help in the management of the disease in the next years. 
Expert commentary: The clinical exploitation of NGS-based characterization of MM patients has 
as its ultimate goal the precision medicine. Considerable obstacles to its implementation in 
myeloma management exist; therefore, the concerted effort of all involved stakeholders is 
mandatory to ensure that it will become a reality in routine clinical practice in the next future. 
Keywords: next-generation sequencing; plasma cell dyscrasias; precision medicine; 
prognostication; response assessment; somatic mutations; tumor evolution.  
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1. Introducing multiple myeloma 
Multiple myeloma (MM) is a malignant proliferation of antibody-secreting bone marrow (BM) 
plasma cells (PCs) that accounts for 10% of all hematological malignancies with an incidence in 
Western countries of about 3-5 per 100,000. PC dyscrasias show a wide clinical presentation 
spanning from the presumed pre-malignant condition of monoclonal gammopathy of undetermined 
significance (MGUS) to smoldering MM (SMM), symptomatic MM, and extra-medullary MM or 
plasma cell leukemia (PCL) [1]. PCL can be primary (pPCL) if originating de novo without any 
previous experience of MM, or secondary (sPCL) when arising from a preexisting myeloma tumor 
that eventually progressed to the leukemic phase [2, 3, 4]. 
Similarly to the clinical course, also the genetic background of the disease is highly 
heterogeneous as featured by a deep genetic instability, at both karyotypic and mutational level. 
Karyotypic instability involves structural and numerical aberrations [1, 5]. About half of MM patients 
are hyperdiploid, carrying non-random trisomies of odd chromosomes and small incidence of 
chromosomal translocations at the immunoglobulin heavy chain (IGH) locus (14q32). The other 
cases are non-hyperdiploid and often display the constitutive activation of CCND1 (11q13), 
CCND3 (6p21), MAF (16q23), MAFB (20q11), or FGFR3/MMSET (4p16.3) genes, resulting from 
IGH translocations. Hyperdiploidy typically implies a better outcome, while t(4;14) and t(14;16) 
translocations are related to a dismal prognosis. In addition, imbalances of specific chromosomal 
portions including 17p13, 1p, 16q, 14q losses and 1q gains are negative prognostic factors [1, 6, 7, 
8, 9]. Despite the recent advent of more efficient drugs (new generation proteasome inhibitors and 
immunomodulatory agents, and monoclonal antibodies) that have improved patient outcome and 
quality of life, most of patients relapse. In addition, in high-risk cases the disease is characterized 
by poor prognosis and short survival, not always predicted by the actually recommended risk 
stratification models, which combine biologic criteria (serum beta-2 microglobulin, albumin and 
lactate dehydrogenase levels) and cytogenetic abnormalities [17p13 deletion, t(4;14), and t(14;16)] 
[10, 11]. Thus, the definition of new markers is made urgent, for not only improving risk prediction, 
but also to guide towards a more appropriate therapeutic strategy, taking full advantage of the 
available additional novel treatment options. This scenario has definitely represented an important 
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rationale behind the efforts to characterize the genetic landscape of MM cells made in the recent 
years by means of next generation sequencing technologies (NGS). Here, we describe how NGS 
has improved our knowledge of MM biology by discovering its mutational landscape, identifying the 
mutational processes operative in the disease, and revealing its complex clonal composition and 
evolution. Furthermore, we discuss the clinical implications of NGS in terms of prognostication, 
therapeutic choices, and response assessment in the disease. Finally, we provide a quick outlook 
of future applications of these technologies that could contribute to further dissect the biology of 
MM cells and help in the management of the disease in the next future. 
 
2. Whole-genome and whole-exome sequencing findings in MM 
2.1 Mutational landscape 
Three main studies analyzed large cohorts of MM patients by means of whole genome sequencing 
(WGS) and whole exome sequencing (WES). In particular, Lohr and colleagues analyzed a total of 
203 tumor-normal pairs collected from 93 untreated and 101 previously treated patients, 177 of 
whom by WES and 26 by WGS [12, 13]; Bolli et al. profiled by WES 67 patients (52 at diagnosis 
and 15 treated), 15 of whom serially analyzed [14]; Walker and colleagues performed WES in 463 
newly diagnosed MM patients enrolled in the UK National Cancer Research Institute Myeloma XI 
trial [15]. 
The emerging scenario from these studies indicates only a few genes found mutated at a 
significant frequency in each of the analyzed cohorts, some of which highlighting key pathways 
commonly deregulated (Figure 1). 
KRAS and NRAS kinases are by far the most frequently mutated genes in MM (on average in 23% 
and 21% of patients, respectively). Along with BRAF (Figure 2), mutated to a lesser extent (8.7% of 
cases) but still at high statistical significance, they contribute to make the mitogen-activated protein 
kinase (MAPK) pathway the main target for somatic mutation in MM, as confirmed by a targeted 
resequencing analysis on a large representative panel of patients at different stages of PC 
dyscrasia [16]. Notably, the classic V600E variant is carried by less than half of the BRAF-mutated 
patients, unlike what observed in other tumor types, i.e. melanoma, colorectal cancer, and papillary 
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thyroid carcinoma. Mutations in the RAS/MAPK pathway are reported to have no impact on 
survival [15]. 
The involvement in MM of DIS3 and FAM46C, which are two of the most recurrently mutated 
genes in the disease (average mutation frequency of 6.8% and 9.1%, respectively) (Figure 3), was 
totally unexpected prior to the application of massively parallel sequencing. DIS3 belongs to the 
human exosome complex; it is endowed with both exo- and endonucleolytic activities and 
regulates the processing and amount of all RNA species [17]. Although the significance of its 
alteration in the disease still needs to be further elucidated, it is considered a potential tumor 
suppressor in MM based on several findings: the loss of enzymatic activity caused by the MM-
associated DIS3 mutations that have been functionally characterized [18]; the loss of 
heterozigosity often involving DIS3 due to simultaneous gene mutations and chromosome 13 
deletion [19]; and the reported enhanced translation of crucial oncogenes following DIS3 
inactivation [20]. Similar to DIS3, FAM46C is an RNA-binding protein whose exact functions remain 
to be characterized, but potentially regulating gene expression [21]. FAM46C too has a putative 
tumor suppressor role in MM, as suggested by the deletion of its genomic locus at 1p12, occurring 
in approximately 20% of MM patients [22], and the predominantly inactivating nature of MM-
associated gene mutations [23]. Overall, the significantly recurrent alteration of DIS3 and FAM46C 
suggests a role of translational control processes in the pathogenesis of MM [12]. 
TP53 is mutated at a significant recurrence rate in all three studies (on average 8.3%), although 
the mutational frequencies observed in each series are significantly different, and higher in series 
where advanced disease was over-represented [13, 14] (Figure 4). In fact, as highlighted by an 
NGS-based analysis in a representative cohort including patients with newly diagnosed MM and 
more advanced stages of PC dyscrasia, TP53 gene mutations are generally rare in MM at onset, 
and conversely constitute a marker of progression, analogously to 17p-deletion [24]. The 
incapacity to trigger an efficient apoptotic response to DNA damage (as defined by combining 
TP53 alterations with mutations observed in ATR, ATM, ZFHX4 or NCKAP5 genes, also involved 
in the DNA-repair pathway) represented the most significant prognostic mutational marker in the 
Myeloma XI trial [15]. 
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Based on the three studies considered above, the process of B cell differentiation resulted 
frequently targeted by mutational events. Particularly affected were the genes encoding the SP140 
nuclear body protein, i.e. the interferon-inducible lymphoid-restricted homolg of SP100; the 
lymphotoxin beta LTB, that is involved in physiological lymphoid development and in the induction 
of the inflammatory response system; and the transcription factors PRDM1 and IRF4, essential to 
plasma cell differentiation. Average mutation rates of SP140, LTB, PRDM1 and IRF4 genes are of 
3.6%, 2.8%, 1.6% and 1.5%, respectively. Notably, mutations affecting IRF4, a target of the IMID 
drugs whose inhibition is toxic to MM cell lines [25], are preferentially represented by the K123R 
variant and have been reported to have a positive impact on survival in the Myeloma XI trial [15]. 
EGR1 is a transcriptional regulator inducing apoptosis in MM cells, where its knockdown enhanced 
resistance to Bortezomib [26]. Similarly to IRF4, EGR1 is an IMID target whose mutations, 
detected in 4.3% of MM patients and clustered at the 5’ end of the gene, were found correlated 
with good overall survival by Walker and colleagues [15].  
The identification of mutations in multiple components of the NF-ĸB signalling (especially TRAF3, 
with an average mutation rate of 3.9%, CYLD, mutated in 2.6% of cases, and the aforementioned 
LTB) further supported and extended the anticipated role of this pathway [27, 28] and widened our 
knowledge on the mechanisms of its activation in MM. 
Among the genes found mutated in MM patients, some are involved in cell cycle regulation, in 
particular RB1 and CCND1, altered respectively in 1.3% and 2.7% of patients; this latter seems to 
be associated with a negative impact on survival [15]. 
 
2.2 Mutational signatures 
Two main studies employed non-negative matrix factorization (NMF) to extract mutational 
signatures from WES data and shed light on the mutational processes contributing to the MM 
mutational landscape [14, 29]. NMF analyses identified at least two mutational signatures: the most 
frequent was called Signature A, it corresponds to signatures 1 and 5 in the paper of Alexandrov et 
al. [30] and is a quite general signature characterized by C > T mutations in a CpG context, a 
process attributed to the spontaneous deamination of methylated cytosine and its conversion to 
 7
thymine. In a small percentage of patients characterized by a high mutational load, a significant 
fraction of the mutational repertoire is ascribable to Signature B, a second signature that 
corresponds to Signature 2 in the paper of Alexandrov et al. [30]. This signature results from the 
aberrant activity of APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) 
family of DNA editing enzymes. Interestingly, APOBEC signature is enriched in MM patients 
harboring t(14;16) and t(14;20) translocations overexpressing respectively MAF and MAFB 
transcription factors, which likely control APOBEC3B and APOBEC4 expression [29]. Recently, 
also a novel signature characterized by small peaks at “C>T GCA” and “C>T GCC” motifs has 
been reported as significantly enriched in acquired mutations in two MAF-translocated patients 
[31]. 
While aberrant APOBEC activity has been associated with a higher load of mutations 
overall, sometimes it results in areas of localized hypermutation, a phenomenon called kataegis, 
that it is often found at the boundaries of somatic genomic rearrangements. Another instance of 
aberrant somatic hypermutation is mediated by off-target activity of AID, a deaminase responsible 
for somatic hypermutation during normal differentiation of germinal center B-lymphocytes 
undergoing antigen selection in adaptive immunity. Instances of mutations within AID recognition 
motifs have been found in the partner oncogenes of IGH translocations [14, 29], and their role in 
myeloma pathogenesis remains to be elucidated.  
Finally, the examination of mutational signatures over time in a small fraction of patients 
indicated that the relative contribution of diverse mutational processes involved in the generation of 
the mutational repertory in MM may change over time [14]. 
 
2.3 Clonal heterogeneity 
Massively parallel-sequencing studies [13, 14] corroborated the intratumor heterogeneity of MM 
anticipated by several phenotypic, molecular and clinical findings [32]. Beyond the major tumor 
clone, indeed, nearly all patients had evidence of clonal heterogeneity, carrying variants occurring 
only in a portion of MM cells. The awareness that intra-clonal heterogeneity is an hallmark of MM 
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biology has modified our way of approaching cancer, now considered as a composite mixture of 
clones and not as a linear evolving disease [33]. 
The subclonal nature of not only supposed passenger mutations but also supposed driver 
mutations, such as those in KRAS, NRAS, and BRAF genes, indicates that these latter might occur 
late in the evolution of the disease, reflecting a dynamic mutational process. In several cases, 
multiple mutations in oncogenes with redundant functions (i.e. KRAS, NRAS and BRAF genes) 
were seen in the same tumor sample, although generally these mutations did not co-occur clonally. 
In this regard, a single-cell analysis of multiple mutations in the RAS/MAPK pathway within the 
same MM tumor revealed the occurrence of convergent evolution, consisting in the acquisition of 
redundant advantageous mutations by distinct clones, which subsequently evolve independently 
[34]. As discussed later in the text, the subclonal nature of variants affecting driver genes and 
multiple coexisting substitutions in the same pathway has important therapeutic implications. 
WES and WGS on a small cohort of patients at various phases of PC dyscrasia (four 
MGUS, four high-risk SMM, 26 MM and two PCL samples, including four MM cases who evolved 
from SMM) indicated that the genetic complexity increases with disease stage [35]. However, 
intraclonal heterogeneity appears to be a premature event in myelomagenesis, already present 
before the occurrence of clinical symptoms, suggesting that immortalized plasma cells diverge very 
early in their evolution. Intra-tumor diversity is critical for disease progression, being the essential 
substrate for underlying Darwinian-like tumor evolution, as discussed further in the following 
paragraph. 
 
2.4 Clonal evolution 
The application of massive parallel sequencing revealed a previously unsuspected model of 
genomic evolution in MM, that diverges from the traditional dogma of genomic aberrations linearly 
accumulating over time. It rather suggests a Darwinian branching model of tumor evolution, with 
several clonal progenitors present at diagnosis whose dominance alternates over time under 
selective pressures exerted by microenvironment or therapy [36, 37]. Along with branching 
evolutionary pathways, responsible for the presence of one or more new clones (likely evolving 
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from ancestral minor clones with newly acquired mutations) and the decreased frequency or loss of 
others, additional patterns of tumor evolution observed in serially analyzed MM patients include: 
clonal stability (i.e. no change in the clonal composition), linear evolution (i.e. the emergence of a 
new subclone), and differential clonal response. This latter pattern consists in an alteration of the 
relative proportions of each subclone which may be related to their random drift in the course of 
time; different response to therapy among subclones; or subclone expansion due to selective 
advantage [14]. 
To gain further information about the pattern of evolution underlying relapse in MM, a 
recent longitudinal study investigated by WES, gene expression profiling and high-resolution copy 
number arrays 33 patients enrolled in Total Therapy protocols with the aim to define specific 
drivers of relapse in the precise context of a standard treatment [31]. Notably, the 
acquisition/expansion of mutations in known MM driver genes (NRAS, KRAS, BRAF) and the 
biallelic inactivation of tumor suppressor genes, especially TP53, proved to be critical events 
driving relapse through the escape form treatment-induced apoptosis and increased proliferation, 
leading to drug resistance and tumor progression. In particular, biallelic events resulting in 
complete inactivation of TP53 defined the group with the worst outcome after relapse. The excess 
of biallelic events and copy number changes from presentation to relapse in high-risk cases were 
consistent with increased genomic instability associated with these patients. The Authors proposed 
a model combining “Big Bang” and Darwinian type of evolution, in which “Big Bang” dynamics lead 
to the early establishment of intratumor heterogeneity, followed by Darwinian-type evolution, in 
which different subclones acquire additional aberrations and compete with each other and normal 
hematopoiesis to access to an appropriate bone marrow niche. In this scenario, treatment 
generates a significant evolution bottleneck, which eradicates some subclones but may 
simultaneously select for clones with strong driver events that increase proliferation and resistance 
to apoptosis. 
Finally, it is worth reporting that a very recent analysis of the distributions of variant allele 
frequencies determined from WES data of 463 patients from the UK Myeloma XI trial indicated that 
nearly 20% of MM tumors at diagnosis are under neutral evolutionary dynamics, consistent with 
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the lack of natural selection during malignant growth [38] (Johnson et al., 16th International 
Myeloma Workshop, abstract # 508). Neutral evolution seemed to be associated with IgH 
translocations, gain of 1q21, and reduced responsiveness to microenvironment-modulating IMiD-
therapy. Further studies may help to confirm and extend these data. 
 
2.5. pPCL 
PPCL is an infrequent, aggressive form of PC dyscrasia and may constitute an effective model for 
high-risk MM. A recent WES study investigated the mutational profiles of 12 pPCL patients enrolled 
in a multicenter prospective GIMEMA Phase II trial (www.clinicaltrials.gov as #RV-PCL-PI-350, 
www.clinicaltrialsregister.eu as #EudraCT N° 2008-003246-28) [39]. Few genes were found 
recurrently mutated in two or more samples, confirming a substantial heterogeneity of mutational 
patterns, as observed in intramedullary disease. Concerning the genes found recurrently mutated 
in MM, mutations in KRAS and NRAS were three-fold less frequent, while those in DIS3 and TP53 
were till to two-fold more recurrent in pPCL than in MM, and this was perhaps at least partly related 
to different representativeness of cytogenetic abnormalities in pPCL and MM series. Globally, 
extracellular matrix (ECM) components, the cadherin/Wnt signaling pathway and cell cycle 
checkpoint were found enriched in mutational events. Also based on gene expression data, the 
Authors speculated that alterations of ECM-receptor interaction and of cadherin/Wnt signaling 
pathway may be strongly involved in the mechanisms of extramedullary spread associated with 
pPCL. On the other hand, the recurrent involvement of DNA damage response genes [specifically 
TP53, ATM, ATR and other downstream genes associated with DNA repair activity (CHEK2, 
CDC25A, CDKN1A, BRCA1)] was suggestive of a potential primitive pathogenetic role of impaired 
DNA repair functions in pPCL, unrelated to therapy [39]. Investigations in larger collections are 
needed to further dissect the molecular mechanisms responsible for this aggressive form of PC 
dyscrasia. 
 
3. Clinical implications of NGS-derived data 
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The information made available by the application of NGS technologies in MM has potential 
relevance in the clinical setting at various levels, including prognostic stratification, therapeutic 
choices and response assessment. 
3.1. Prognostication 
To date, the potential of NGS in MM prognostication has not yet been fully exploited. In fact, the 
prognostic significance of the mutational spectrum characterizing MM has been assayed virtually 
only by Walker and colleagues within the clinical trial Myeloma XI, comparing a standard 
chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer 
regimen of cyclophosphamide, dexamethasone plus lenalidomide [15]. In the context of this study, 
while mutations in MAPK and NF-ĸB pathways, as anticipated above, are prognostically neutral, 
variants in CCND1 and DNA repair pathway correlate with poor survival, and those in IRF4 and 
EGR1 appear to be associated with better prognosis. Notably, some of these new prognostic 
factors (including mutations in TP53, ZFHX4, CCND1, ATM and ATR) were combined with adverse 
cytogenetic abnormalities, such as del(17p), t(4;14), amp(1q) and MYC translocations, and the 
International Staging System (ISS) to generate a risk score able to better identify high-risk patients 
experiencing relapse and premature death [15]. Although an external validation of this predictive 
tool is required, the Authors envisaged an easy incorporation of the detection of these molecular 
markers in a diagnostic test that could be developed in the everyday practice. 
Beyond mutations affecting single genes, the prognostic power of patients’ global 
mutational load is uncertain. Indeed, while Bolli et al. reported a positive correlation between the 
amount of variants and the extent of the risk of relapse and death [14], Weinhold and colleagues 
found no association between the mutational load and GEP70 risk status either at presentation or 
relapse, after adjustment for the UAMS (University of Arkansas for Medical Sciences) molecular 
calssification [31, 40]. 
 
3.2. Therapy 
Concerning the therapeutic implications of the application of NGS-based technologies in MM, it is 
conceivable that the definition of MM mutational landscape may help towards the identification of 
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specific treatments from which patients may particularly benefit, or otherwise to be avoided. This 
could be the case of patients carrying mutations associated with a clinical response to specific 
therapies or representing druggable targets. NRAS, IRF4 and EGR1 are examples of genes that, 
when mutated, seemed to be associated with a different response to treatments currently used in 
myeloma. In particular, an association was reported between the reduced sensitivity to bortezomib 
and the presence of NRAS mutations at relapse, having a negative impact on both response rate 
and time to progression [41], whereas IRF4 and EGR1 mutations correlated with better outcome 
with immunomodulatory agent therapy [15]. Another important finding of more general nature but 
with potential implications on therapeutic choices has recently emerged from the aforementioned 
longitudinal WES study by Weinhold and colleagues on MM patients relapsed after treatment with 
high dose therapy [31]. Indeed, the identification of the bi-allelic loss of tumor-suppressor genes, 
such as TP53, as a crucial mechanism allowing MM cells to evade treatment-induced apoptosis 
with the acquisition of proliferative advantage suggests the employment of alternate therapies 
during the post-induction phase, especially treatments inducing cell death via tumor-suppressor 
independent pathways. 
Even more appealing is the perspective of directing therapy specifically to driver mutations, 
which are known to provide a fitness advantage to MM cells, by means of agents selectively 
inhibiting the mutated or activated oncogene. Notably, the most recent and comprehensive WES 
study in MM overall detected potentially druggable mutations in 309 target genes and involving the 
53% of patients, suggesting an even broader applicability of targeted therapies in MM in the 
coming years (Table 1) [15]. Single agents targeting specific mutations are not currently approved 
for routine clinical use in MM, but several of such molecules are in clinical testing, and a few 
experiences concerning their successful employment in MM patients have begun to be reported, 
for example for the V600E-mutated BRAF inhibitor Vemurafenib [42, 43] and the MEK inhibitor 
trametinib [44]. Other actionable mutations include those affecting FGFR3, CCND1, and the 
pathway of NF-kB [27, 28], just to name a few. Although tailored therapies are promising, some 
biological aspects of the disease that may limit severely their effectiveness must be taken into 
consideration. Concerning the inhibition of MAPK pathway, for instance, Lohr and colleagues [13] 
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reported a paradoxical increase in pERK and in cell proliferation in BRAF-wild type MM cell lines 
treated with Vemurafenib, as already observed in melanoma [45]. Notably, MAPK pathway 
activation was even more pronounced in the presence of KRAS or NRAS mutations. Translated in 
a clinical setting, these data cast doubts on the potential benefits of the use of BRAF inhibitors, 
especially if used as monotherapy, in MM patients harboring subclonal BRAF mutations or co-
existent BRAF and RAS mutations in different cells of the same tumor. Under such circumstances, 
BRAF inhibitors may lead to paradoxical expansion of, respectively, BRAF-wild-type and RAS-
mutated subclones and hence to clinical progression. The latter scenario was recently described in 
one instructive case, where a proteasome inhibitor-based therapy (bortezomib/dexamethasone) 
was used to overcome resistance to vemurafenib [46]. 
Furthermore, clonal heterogeneity might represent a major obstacle to the success of 
targeted therapies pinpointed to one genetic lesion. Indeed treatment directed against a mutation 
carried only by a subset of tumor cells is expected to be effective exclusively on that subclone, with 
a consequent restricted clinical benefit, which makes at least necessary to resort to a combination 
of different types of treatment targeting distinct subclones. 
On the other hand, even genes mutated in most of the tumor population do not necessarily 
have an important biological impact. Targeted treatment based solely on DNA sequencing data, in 
fact, could be ineffective if that mutated gene is not expressed. Indeed, a recent RNA-seq analysis 
of a subset of patients who had previously undergone WES showed that most of the reported 
mutated genes have very low or undetectable expression [47]. 
 
3.3. Response assessment 
NGS could also meet another strong need that is emerging in the management of MM patients, i.e. 
the determination of minimal residual disease (MRD) [48, 49]. While achievement of a 
morphological and serological complete remission was rare in the past, novel treatments have 
resulted in an increased occurrence of these events so that nearly all patients show a response to 
treatment and most achieve a complete response (CR) [50]. However, the increased effectiveness 
of treatment approaches in the past decade has not been accompanied by a better definition of 
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CR, which conversely remains based on conventional serological and morphologic techniques, 
with the result that most patients achieving CR ultimately relapse and die. This scenario is mainly 
attributable to the persistence of MRD undetected by conventional response assessment methods 
[49]. Newer and more sensitive techniques to detect MRD in BM aspirates include multiparameter 
flow-cytometry (MFC), allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) and 
NGS. Although currently none of these techniques fully satisfies all the characteristics that the ideal 
MRD test should possess (i.e., high applicability, high sensitivity and specificity, good feasibility, 
easy accessibility, requirement for a limited sample, reproducibility, and proven clinical outcome), 
NGS fulfills most of them. In particular, MRD assessment by NGS is mainly, although not 
exclusively, based on the LymphoSIGHT platform (Adaptive Biotechnologies), which consists in 
genomic DNA amplification by multiplexed PCR assays using consensus primer sets allowing the 
recognition of all known alleles of the germline IGH and IGK sequences, followed by sequencing 
and identification of cancer-associated clonotypes with a minimum frequency of 5% [51]. The 
tumor-derived sequences detected in the samples at diagnosis are used as targets in follow-up 
samples to assess the presence of MRD, defined as the number of cancer-derived molecules per 
one million cell equivalents. Compared with ASO-PCR, NGS-based MRD assessment proved to be 
at least comparable in terms of sensitivity [52], and recent studies in chronic lymphocytic leukemia 
and acute lymphoblastic leukemia indicated that a sensitivity of one in 1,000,000 is achievable by 
NGS when higher amounts of DNA are used [53, 54]. Furthermore, contrary to ASO-PCR, NGS-
based monitoring of MRD does require neither use of patient-specific primers, nor creation of a 
standard curve for quantitation. This latter and other limitations of quantitative ASO-PCR could be 
overcome, at the same performance level, by droplet digital PCR, especially in terms of reduced 
labor intensiveness and easier data interpretation, although its potential advantages and predictive 
value need to be further studied in the context of prospective clinical trials [55]. On the other hand, 
compared with NGS, MFC has the advantages of requiring less time to generate results, of being 
virtually applicable to all patients, and of not requiring a baseline sample. However, although a 
sensitivity higher than 10-5 is achievable by means of the new MFC instruments, up to 2x106 cells 
are required. In addition, further efforts are needed to conform the flow-based approaches and limit 
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the subjectivity linked to individual interpretations. Finally, the need to work on fresh samples 
makes the transfer of MFC in clinical settings more complex. Nevertheless, NGS too has 
limitations: besides that fact that it can be limited in its ability to capture a clonotype in all patients 
in spite of adequate samples, there are still several issues with quantification, among which the 
calibration and correction approaches used to determine total leukocytes, B-lineage cell numbers, 
and reproducibility of quantification (in particular considering that it depends on DNA quantity and 
sequencing depth) [56]. Furthermore, additional checks are required to determine whether a 
negative result is attributable to sample quality (e.g., morphology and/or flow cytometry). 
The clinical significance of sequencing-based MRD assessment in MM patients was recently 
reported in two studies by the same group [51, 57]. In particular, the most recent one adopted an 
in-house deep-sequencing method using the standardized primers developed by the Biomed-2 
concerted action to amplify all IGH or IGK sequences in a patient sample [58]. Differently from the 
proprietary multiplex PCR entailed by the LymphoSIGHT method, to be performed at centralized 
laboratories, this approach can be implemented in any laboratory with NGS capability, thus 
shortening turn-around time, and can be fully automated, and hence easily standardized reducing 
inter-lab variation [57]. Latest recommendations of the International Myeloma Working Group 
(IMWG) (2016) strongly encouraged the inclusion of next-generation sequencing and next-
generation flow in prospective trials to find out the pros and cons of the single approaches, and the 
sensitivity required in different clinical settings. Notably, to harmonize the definition of MRD status 
across studies, the IMWG revised the response criteria for myeloma and included MRD negativity 
as the highest degree of response to treatment [59]; in particular, sequencing MRD-negativity was 
defined as absence of clonal PCs by NGS on BM aspirate. 
 
4. Expert commentary 
The exploitation of NGS-enabled mutational characterization of cancer patients in therapeutic field 
has as its ultimate goal the implementation of precision medicine, i.e. the administration of 
personalized treatment based on the mutational repertoire of each tumor. This process is often 
referred to as matching the right drug to the right patient in the right dose at the right time. A major 
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obstacle to its implementation, however, is the inadequacy of many current clinical trial designs. 
Such inadequacy is related to the fact that targeted approaches rely on increasing amounts of 
therapeutic agents, whose potential combinations and conceivable sequential administration 
options are even exponentially more numerous. Furthermore, myeloma, like most cancers, is not a 
molecularly homogeneous entity, but rather presents several actionable mutations and does not 
nicely segregate into genomically-defined subtypes that could be used to stratify treatment arms 
[60]. In other words, the similarity between patients and the homogeneity between therapy groups 
required for classical clinical trials seem irreconcilable with the molecular intra- and inter-tumor 
diversity and different therapeutic options that constitute the basis of personalized medicine. The 
resulting combinatorial complexity makes it necessary to extend the conventional “basket” and 
“umbrella” approaches developed to study molecularly targeted therapies [61] and to resort at least 
to adaptive designs enabling an ongoing modification of the clinical trial based on the knowledge 
acquired through the trial itself [62]. Even better, precision medicine would require a kind of clinical 
trial focusing on single, not average, treatment responses, and probing the myriad factors that 
shape an individual’s response to a specific therapy [63]. Such a personalization of clinical trials 
might rely on the implementation of oncological N-of-1 trials (which should all be evenly carried out 
and whose results should be aggregated), although there is skepticism towards this approach in 
part of the oncology community, including regulatory agencies, researchers and clinicians [64]. 
Beyond the paradigm shift in clinical trial design needed to fit studies able to effectively 
assessing targeted agents into the regulatory drug approval pathway, another obstacle to the 
realization of precision oncology is the amount of data that must be taken into account and 
integrated, including high-quality NGS data, histopathological and clinical findings. The 
impossibility of processing and interpretation of such a data volume in a meaningful and timely 
manner by clinicians raises the need for machine-learning approaches intended to assist 
oncologists responsible of taking decisions about the treatment of single patients. IBM’s Watson 
Oncology is one of these computing self-learning algorithms currently being tested at some 
institutions [65, 66].  
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In our opinion, those just discussed are the main considerations to be made when thinking 
about a future pervasive application of NGS-enabled tailored medicine in MM, but certainly many 
others exist. After all, precision oncology represents an epochal revolution in patients' 
management, and therefore it is conceivable that it involves substantial changes (at both cultural 
and practical levels) in the way we operate in order to cure cancer, that surely will need a long time 
to be realized. The concerted effort of all stakeholders involved in the development of precision 
oncology (researchers, clinicians, regulatory agencies, governments) is now mandatory to ensure 
that in the future it will become a reality in routine clinical practice. 
 
5. Five-year view 
Considering that the continuous improvement of sequencing technologies will most likely reduce 
costs and processing times, in the near future NGS might really represent a viable option for 
routine clinical practice. In this perspective, clinical-grade approaches to analyze the genomic 
repertoire of MM patients allowing the identification of biomarkers with clinical relevance have 
begun to be developed and certainly will continue to be implemented. In this regard, Kortum and 
colleagues were among the first to demonstrate the practical use of a custom MM-specific gene 
panel for targeted sequencing as a simple, inexpensive and rapid strategy to characterize the 
mutational profile of MM. Specifically, they initially constructed a panel of 47 genes (M3P) [67] 
subsequently updated to a 77 gene version (M3Pv2.0) [68], and more recently further integrated to 
include 88 frequently mutated or drug-resistance pathway MM genes, with a focus on genes 
relevant to IMiD and proteasome inhibitor interactions (M3Pv3.0) [69]. It is worth to point out also 
two recently published studies, both proposing a target-enrichment strategy followed by NGS for 
one-step identification of MM common genetic abnormalities. In particular, Bolli and colleagues 
developed and validated an approach to simplify all-in-one high-throughput analysis of gene 
mutations, DNA copy number changes and IGH translocations in MM independently from matched 
normal samples [70]. Similarly, the strategy proposed by Jimenez et al. allowed the identification of 
IGH translocations, V(D)J rearrangements and IgH isotype (usable as a target for evaluating 
MRD), and somatic mutations in a single run [71]. Although a substantial optimization of capture-
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based NGS panel and of data analysis is still required, these works represent the first appealing 
attempts of introducing NGS-based technologies during routine diagnostic workup for MM. 
An even more widespread and fruitful application of NGS in routine clinical practice might 
be expected if the genetic analysis of circulating MM cells at single-cell level recently reported by 
Lohr et al should prove a viable approach [72]. In particular, by analyzing at single-cell resolution 
circulating tumor cells (CTCs) isolated from peripheral blood of 10 MM patients, the Authors 
demonstrated that the genetic makeup of CTCs recapitulates MM in the bone marrow, even 
revealing mutations with greater sensitivity than bone marrow biopsies in some cases. Although 
larger studies will be required to establish its clinical utility, this approach would virtually allow to 
fully exploiting the potential of NGS, as it would make possible the extensive molecular monitoring 
of MM patients that actually does not occur due to the clinical impracticability of serial bone marrow 
sampling (involving an invasive and painful procedure). In particular, the ability to track the genetic 
evolution of MM could reveal the acquisition of mutations associated with the transition to overt MM 
in MGUS/SMM patients at risk of progression, thus warranting preventive interventions, as well as 
emerging drug resistance mutations in MM patients undergoing treatment, who might be directed 
towards early intervention with mechanism-driven therapies. Notably, recent evidence supports the 
feasibility of non-invasive mutational profiling of PC dyscrasia patients also from circulating cell-
free tumor DNA [73, 74]. 
Continuing to speculate on the future evolution of NGS technology in MM, RNA-sequencing 
is an application of NGS still largely unexplored in the context of the disease [47, 75], and that 
reasonably will produce a substantial amount of new data in the near future. 
In particular, RNA-seq could allow a deeper characterization of coding transcriptome than that 
obtained by means of microarrays, by providing information, as well as on gene expression levels, 
on differential splicing and isoform expression, mutational profiling and gene fusions. This could be 
particularly meaningful in MM, where disease-specific alternate splicing events of several genes 
have been reported [76, 77, 78]. Moreover, RNA-seq is the technology of choice for the discovery 
and genome-wide expression analysis of non-coding RNAs, whose involvement in MM is 
increasingly documented and that are being investigated as a therapeutic target [79, 80]. 
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Furthermore, recent large-scale epigenomic analyses of MM cells have highlighted a 
complex epigenomic landscape contributing to MM onset and prognosis and characterized by 
anomalies in DNA methylation and in post-translational modification of histone proteins [81]. 
However, epigenetic intra-tumor heterogeneity in MM is yet unexplored and, as regards DNA 
methylation, it might be analyzed by DNA methylation profiling through enhanced reduced 
representation bisulfite sequencing (ERRBS), as done by Pan and coworkers in diffuse large B cell 
lymphoma [82]. ERRBS, indeed, is an efficient and high-throughput, NGS-based technique used to 
analyze the genome-wide methylation profiles at single-nucleotide resolution, and provides a 
unique opportunity to quantify intra-tumor DNA methylation heterogeneity (MH) since each 
sequenced read is derived from one individual tumor cell. Given the proved intra-tumor 
heterogeneity characterizing multiple myeloma at various levels (phenotypic, molecular, genetic 
and clinical), it is reasonable to expect the existence of epigenetic intra-tumor heterogeneity as 
well. The perspective of therapeutically targeting aberrant methylation and the prognostic value of 
MH in other cancer types encourage its assessment in MM. 
 
Key issues 
• MM is a malignant proliferation of antibody-secreting bone marrow plasma cells characterized 
by a wide clinical presentation and an extremely heterogeneous genetic background. Despite 
the recent improvement of patient outcome and quality of life thanks to new efficient drugs, the 
majority of patients experiences relapse, and the actually recommended risk stratification at 
diagnosis fails to identify a subgroup of high-risk cases. 
• Recently, the genetic makeup of MM cells is being better characterized by means of NGS 
technologies, with the aim of defining new markers for improved risk prediction and to guide 
towards the most appropriate therapeutic strategy. 
• The general scenario emerging form WGS/WES studies indicates a few genes found mutated 
at a significant frequency of occurrence, among which KRAS, NRAS, BRAF, TP53, DIS3 and 
FAM46C. Besides the MAPK pathway, that is the most recurrently mutated, the non-canonical 
NF-kB signalling is another key target of somatic mutation in MM. 
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• Different processes, among which kataegis and aberrant somatic hypermutations, are involved 
in the generation of MM mutational repertory, whose relative contribution may vary in time. 
• Nearly all patients had evidence of clonal heterogeneity. Even known driver mutations can be 
subclonal in some patients. An analysis at the single-cell level provided clear evidence of 
convergent evolution, consisting in the acquisition of redundant mutations conferring growth 
advantages by distinct clones. Although the genetic complexity increases with disease stage, 
clonal heterogeneity appears to be a premature event in MM pathogenesis and critical for 
disease progression. 
• The application of massively parallel sequencing revealed, along with the traditional model of 
genomic aberrations linearly accumulated over time, a Darwinian branching model of tumor 
evolution, with several clonal progenitors present at diagnosis whose dominance alternates 
over time under selective pressures exerted by microenvironment or therapy. 
• The information made available by the application of NGS technologies in MM is potentially 
reflected in the clinical setting at various levels, including i) prognostic stratification; ii) 
therapeutic choices; iii) response assessment. 
i) Prognostication: a risk score with improved capacity to identify high-risk patients has been 
generated by combining some new mutation prognostic markers, adverse cytogenetic 
abnormalities and ISS [15]. 
ii) Therapeutic choices: in terms of therapeutic applications of NGS-derived data, the most 
appealing perspective is directing treatment specifically to driver mutations, by means of 
agents selectively inhibiting the mutated or activated oncogene. The most recent and 
comprehensive WES study in MM overall detected potentially druggable mutations in 309 
target genes and involving 53% of patients [15]. Although tailored therapies are promising, 
some biological aspects of the disease that may limit severely their effectiveness must be 
taken into consideration, first of all clonal heterogeneity. 
iii) In 2016, the IMWG revised the response criteria for myeloma and included MRD negativity 
as the highest degree of response to treatment. Sequencing-based MRD assessment fulfills 
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almost all the characteristics that the ideal MRD test should possess, and its clinical 
significance is recently being reported [51, 57]. 
• Two major obstacles to the implementation of precision oncology in myeloma management are 
the inadequacy of many current clinical trial designs and the amount of data that must be taken 
into account and integrated, including high-quality NGS data, histopathological and clinical 
findings. The concerted effort of all stakeholders involved in the development of precision 
oncology (researchers, clinicians, regulatory agencies, governments) is mandatory to ensure 
that in the future it will become a reality in routine clinical practice. 
• Some preliminary attempts aimed at introducing NGS-based technologies during routine 
diagnostic workup for MM have been made [68, 69, 70, 71], and certainly will continue to be 
implemented.  
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Table 1. Genes affected by druggable mutations in MM. 
Gene Percentage of mutated MM patients Targeted therapy 
KRAS 23.2% MEK inhibitor 
NRAS 21% MEK inhibitor 
BRAF 8.7% Vemurafenib 
ROS1 3.1% Foretinib 
CCND1 2.7% Pablociclib 
FGFR3 1.5% Masitinib 
MLL 1.2% EPZ-5676 
PIK3CA 1.2% GDC-0941 
FGFR2 1.2% Masitinib 
FLT3 1% Sunitinib 
Genes affected by druggable mutations in MM according to what reported by Walker et al. 
[15] and found mutated in at least 1% of patients when averaging the frequencies reported 
by Walker et al. [15],Bolli et al. [14], and Lohr et al. [13]. 
 
